Multiple sclerosis

Why B-cell therapies, or why not?

3848 2300 Peter Stevenson, PhD

The rational for B-cell therapy in multiple sclerosis (MS) was presented during ECTRIMS 2019, with David Baker (Blizard Institute, Queen Mary University of London, UK) posing the question of why…

read more

Are stem cells in MS ready for prime time?

2300 1535 Peter Stevenson, PhD

Hot topics continued at ECTRIMS 2019 in Stockholm with Joachim Burman (Department of Neurology, Uppsala University Hospital, Sweden), who stepped up to the podium to discuss autologous haematopoietic stem cell transplantation (aHSCT)…

read more

Enough evidence for vitamin D in MS?

3450 2300 Peter Stevenson, PhD

The role of vitamin D in the treatment of multiple sclerosis (MS) took centre stage during the first day of ECTRIMS 2019 in Stockholm, Sweden. In a ‘Hot Topic’ session,…

read more

Natalizumab treatment associated with reduction of gliotic biomarkers in white matter

3067 2300 Michael Furrer, PhD

New data on the effect of natalizumab treatment on neuronal and membrane integrity in lesional white matter were presented at the recent 5th Annual Congress of the European Academy of…

read more

Serum NfL levels shine a light on neuroaxonal damage and disease

4089 2300 Michael Furrer, PhD

The 5th Annual Congress of the European Academy of Neurology (EAN) in Oslo, Norway, featured an in-depth exploration of the role of neurofilament light chain (NfL) protein levels as a…

read more

Cellular power failures linked to Parkinsonism

3150 2100 Mea Holm, PhD

Mounting evidence is linking neurodegenerative disorders, such as Parkinsonism and dementia, with mitochondrial dysfunction.1 At the 5th Annual Congress of the European Academy of Neurology (EAN) in Oslo, Norway, the…

read more

8-year follow-up data of alemtuzumab presented

1920 1280 Michael Furrer, PhD

An update of the long-term efficacy and safety data of alemtuzumab in patients with relapsing-remitting MS was presented at the 5th Annual Congress of the European Academy of Neurology (EAN)…

read more
lab

Establishing sNfL as an MS Biomarker

3300 2200 Carlotta Foletti, PhD

At the ECTRIMS annual congress in October 2018, there was a lot of talk on serum neurofilament light (sNfL) becoming the first blood biomarker predicting neuronal damage caused by neurological…

read more
news

News from the ocrelizumab front

3300 2200 Carlotta Foletti, PhD

In our ongoing coverage of the AAN Annual Meeting in Philadelphia, we are focusing on select posters reporting on studies of ocrelizumab, an intravenous humanised monoclonal antibody that selectively targets…

read more
Brainwork is supported by unrestricted grants from: